KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity (2016 - 2024)
Historic Liabilities and Shareholders Equity for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $294.8 million.
- KalVista Pharmaceuticals' Liabilities and Shareholders Equity changed N/A to $294.8 million in Q4 2024 from the same period last year, while for Apr 2025 it was $655.8 million, marking a year-over-year increase of 114.09%. This contributed to the annual value of $235.4 million for FY2024, which is N/A changed from last year.
- Per KalVista Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $294.8 million for Q4 2024.
- KalVista Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $294.8 million during Q4 2024, with a 5-year trough of $66.2 million in Q1 2021.
- For the 4-year period, KalVista Pharmaceuticals' Liabilities and Shareholders Equity averaged around $143.8 million, with its median value being $126.4 million (2023).
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 3568.17% in 2021, then surged by 2486.47% in 2024.
- Over the past 4 years, KalVista Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $75.4 million in 2020, then dropped by 12.25% to $66.2 million in 2021, then surged by 109.56% to $138.7 million in 2023, then skyrocketed by 112.49% to $294.8 million in 2024.
- Its last three reported values are $294.8 million in Q4 2024, $160.8 million for Q4 2024, and $200.2 million during Q3 2024.